EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura
Por:
Escribano-Serrat, S, Salas, MQ, Pascual-Izquierdo, C, Villalobos, MF, Gomez-Seguí, I, Fidalgo, T, Docampo, MF, Nieto, JM, Lamas, O, Lozano, M, Cid, J, Charry, P, Pino, M, Molina, P, De Moner, B, Ramos, A, Moreno-Castaño, AB, Martinez-Sanchez, J, Escolar, G and Díaz-Ricart, M
Publicada:
17 nov 2025
Ahead of Print:
17 nov 2025
Resumen:
Introduction: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy resulting from severe ADAMTS13 deficiency. Caplacizumab accelerates platelet recovery, but similar to 15% of patients remain refractory, and endothelial/microvascular injury or low ADAMTS13 activity may persist despite remission, highlighting the need for biomarkers. We evaluated the Endothelial Activation and Stress Index (EASIX), an endothelial dysfunction surrogate, dynamics and ability to predict refractoriness and mortality in iTTP.
Methods: Fifty-five adults receiving >= 2 therapies (corticosteroids, plasma exchange, rituximab, and/or caplacizumab) were studied. Clinical and laboratory data were collected at baseline, days 1-2, 7, 14, 21, 28, 35, and at treatment discontinuation, including clinical or ADAMTS13 relapses. EASIX was calculated at each time point; logistic regression and ROC analyses evaluated its predictive performance for refractoriness and mortality.
Results: Median age was 47 years; 13% were refractory, and 7% died. In responders, EASIX dropped below 1 by day 7, earlier than ADAMTS13 recovery (day 21). Clinical relapses showed EASIX spikes (median 13.2), unlike ADAMTS13-only relapses. Baseline EASIX was higher in refractory patients (752 vs. 91; p=0.007), remaining elevated at days 7 and 14. Higher pre-treatment EASIX predicted refractoriness (OR = 1.003; p=0.021; AUC = 0.811; sensitivity 100%; specificity 58.7%) and mortality (OR = 1.004; p=0.027).
Discussion: EASIX may help predict refractoriness and death, improving monitoring in iTTP.
Filiaciones:
Escribano-Serrat, S:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Salas, MQ:
Hosp Clin Barcelona, Hematopoiet Transplantat Unit, ICAMS, Barcelona, Spain
Pascual-Izquierdo, C:
Hosp Univ Gregorio Maranon, Hematol Dept, Inst Invest Gregorio Maranon, Madrid, Spain
Villalobos, MF:
Hosp Univ Gregorio Maranon, Hematol Dept, Inst Invest Gregorio Maranon, Madrid, Spain
Gomez-Seguí, I:
Hosp Univ La Fe, Hematol Dept, Valencia, Spain
Fidalgo, T:
Ctr Hosp Univ Coimbra, Coimbra, Portugal
Docampo, MF:
Inst Invest Biomed A Coruna INIBIC, Area Gest Integrada A Coruna, La Coruna, Spain
Nieto, JM:
Hosp Clin San Carlos, Madrid, Spain
Lamas, O:
Hosp Univ La Fe, Hematol Dept, Valencia, Spain
Lozano, M:
Hosp Clin Barcelona, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit, ICAMS, Barcelona, Spain
Cid, J:
Hosp Clin Barcelona, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit, ICAMS, Barcelona, Spain
Charry, P:
Hosp Clin Barcelona, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit, ICAMS, Barcelona, Spain
Pino, M:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Molina, P:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Ramos, A:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Moreno-Castaño, AB:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Martinez-Sanchez, J:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Escolar, G:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Díaz-Ricart, M:
Hosp Clin Barcelona, Hematopathol Pathol Dept, Lab Hemostasis & Erythropathol, CDB, Barcelona, Spain
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Green Submitted, gold
|